Academic Journals Database
Disseminating quality controlled scientific knowledge

Novel Combinations for the Treatment of Metastatic Breast Cancer

Author(s): Linda T. Vahdat

Journal: Cancers
ISSN 2072-6694

Volume: 2;
Issue: 1;
Start page: 1;
Date: 2010;
Original page

Keywords: metastatic breast cancer | anthracycline failure | taxane failure | combination therapy | chemotherapy | targeted or biologic therapy | outcomes | survival

Anthracyclines and taxanes represent the mainstay of first-line cytotoxic therapy for metastatic breast cancer (MBC), but most patients eventually develop resistance to these agents. Consequently, alternative combinations for MBC therapy are the subject of much ongoing research. Capecitabine and ixabepilone is the only chemotherapy combination specifically approved for MBC after failure of anthracyclines and taxanes. Other options have limited data to support their use in this setting but are commonly used in practice. Future MBC therapies will likely combine alternative chemotherapies and novel biologic agents, and numerous ongoing trials should help to further define the proper use of these regimens.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?